325 results about "Cyclodextrin Derivatives" patented technology

This invention is directed to compositions comprising a water-miscible organic solvent or solvent mixture and one or more cyclodextrin derivatives soluble in the organic water-miscible organic solvent or solvent mixture. In some embodiments, the composition comprises one or more compounds. The invention is further directed to capsules containing the compositions of the present invention and the administration of pharmaceutically active compounds or molecules to subjects. The invention also includes methods of enhancing the solubility of a compound comprising forming a complex or mixture of a compound with a hydroxybutenyl cyclodextrin and a water-miscible solvent.

A barrier film composition can comprise a thermoplastic web comprising a thermoplastic polymer and a dispersed cyclodextrin composition having substituents that compatibilize the cyclodextrin in the film. The thermoplastic / cyclodextrin film obtains substantial barrier properties from the interaction between the substituted cyclodextrin in the film material with a permeant. The substituents on the cyclodextrin molecule causes the cyclodextrin to be dispersible and stable in the film material resulting in an extrudable thermoplastic. Such materials can be used as a single layer film material, a multilayer film material which can be coated or uncoated and can be used in structural materials wherein the thermoplastic is of substantial thickness resulting in structural stiffness. The cooperation between the cyclodextrin and the thermoplastic polymer provides barrier properties to a web wherein a permeant can be complexed or entrapped by the cyclodextrin compound and held within the film preventing the permeant from passing through the film into the interior of a film, an enclosure or container. The permeant can comprise a variety of well known materials such as moisture, aliphatic or aromatic hydrocarbons, monomer materials, off flavors, toxic compounds etc.

The present invention relates to development of efficacious pharmaceutical compositions comprising an anti-angiogenic compound in a therapeutically effective amount complexed with or encapsulated in a cyclodextrin derivative.

A sulfoalkyl ether-alkyl ether cyclodextrin (SAE-AE-CD) derivative is provided. The SAE-AE-CD possesses advantages over known SAE-CD and AE-CD derivatives as well as over the parent cyclodextrin by being more water soluble and less membrane disturbing. The SAE-AE-CD includes at least one sulfoalkyl ether group and at least one alkyl ether group even though the degree of substitution for the functional groups can be different. The SAE functional group can be present in molar excess over the AE functional group and vice versa. The total degree of substitution of the cyclodextrin, with respect to both functional groups, can be varied such that a minority or a majority of the hydroxyl moieties of the CD are derivatized. The SAE-AE-CD derivative can be used to solubilize compounds with insufficient water solubility. In some cases, they also stabilize compounds in solution against degradation or to solubilize degradation products formed during degradation. In addition, SAE-AE-CD can also be used for other purposes such as osmotic agents, agents used to mask the taste of problematic drugs. Surprisingly, while AE-CDs are known to be toxic by being membrane disturbing, SAE-AE-CDs are less membrane disturbing and therefore have greater safety.

Disclosed herein are methods of delivering drugs or therapeutically active agents to the back of the eye via topical administration of compositions comprising cyclodextrin derivatives. Compositions related thereto are also disclosed herein.

The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and / or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.

The present invention relates to a process of preparing a water-soluble complex of water-insoluble or sparingly-soluble organic medicines and beta-cyclodextrin derivatives: a. dissolving successively or simultaneously the organic medicines and the beta-cyclodextrin derivatives in organic solvent(s) at certain mole ratio or mass ratio in the presence of suitable amount of water; b. removing the organic solvent from the solution of the step a to obtain aqueous solution of the organic medicine and beta-cyclodextrin derivative; and c. removing water from the aqueous solution to obtain the complex of the organic medicine and beta-cyclodextrin derivative. The invention also provides a sterile water-soluble complex of water-insoluble or sparingly-soluble organic medicines and beta-cyclodextrin derivatives. A fully-water-soluble complex can be prepared from any water-insoluble or sparingly-soluble organic medicines or other organic compounds according to the present invention. Thus, appreciably convenient means are provided for industrial uses of such organic medicine preparations and of other organic compounds.

The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.

The invention provides a high-COD (Carbon Oxide Demand) special non-phosphorus corrosion and scale inhibitor and preparation method thereof. The corrosion and scale inhibitor mainly comprises cyclodextrin or cyclodextrin derivatives, a soluble metal salt, a copolymer containing a sulfonic acid group, a homopolymer containing carboxylic acid, an acrylic acid / ethyl acrylate / 2-acrylamide-2-methallylsulphonate copolymer, tetrahydroglyoxaline matters, sodium gluconate, and quaternary ammonium salt. The non-phosphorus corrosion and scale inhibitor is suitable for an open circulated cooling water system, and suitable for surface water high in COD and free of treatment, and the non-phosphorus corrosion and scale inhibitor is added into the circulated cooling water system by an automatic reagent feeding device. The non-phosphorus corrosion and scale inhibitor is environmentally-friendly, avoids using phosphorous compounds or non-renewable molybdate or tungstate, has the characteristic of being free from phosphorus and nitrogen, meets the requirement of environmental protection, reduces the environmental burden, has a sterilizing ingredient at the same time, and effectively reduces the problems of bacterial corrosion and algae growth in a circulated water system.

The invention discloses a water-soluble drug composition of taxol for injection. The drug composition comprises taxol as an active component, polyethyleneglycol 15- hydroxy stearic acid ester as a solubilizer, alcohol as a latent solvent and injection water as a solvent. Polysorbate, cyclodextrin derivatives, poloxamer, polyethylene glycol (PEG) and reducing sugar are also added and are favorable for improving the solubility and stability of the taxol in the composition. The composition is prepared to freeze-dried powder injection for injection, can not produce serious anaphylactic reaction, has small simulation, remarkably improves the clinical compliance of patients and has good water solubility and high convenience for medication by clinicians. The powder injection has good stability, can be stored at room temperature and is favorable for storage and transportation. The powder injection is simple in preparation process, easy to control quality, low in production cost and convenient for industrialized production and also greatly reduces the economic burden of the patients for medication. The invention also discloses a method for preparing the drug composition and clinical application thereof.

The present invention features that silybin is included by cyclodextrin or its derivative so as to dissolve in water to prepare injection. The present invention solves the problem of water insoluble silybin for being suitable for intravenous injection.

The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and / or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD.

A composition for medicine having arctigenin and a method for preparing the same, in particular the arctigenin is involved in a cyclodextrin derivative, which mixture ratio is in a range of 1g:3g-30g, and the composition can effectively increase solubility and bioavailability of the arctigenin.

The invention relates to a butyl phthalide tablet and a preparation method thereof. The butyl phthalide tablet is composed of butyl phthalide solid powders and other medical troche auxiliary materials; wherein, the butyl phthalide solid powders are composed of the components with the following weight percentage: 9 percent to 30 percent of butyl phthalide, 0.01 percent to 1.2 percent of emulsifiers and 70 percent to 90 percent of cyclodextrin or cyclodextrin ramification. The troche which is made with the invention has favorable forming, stable product quality and high dissolution rate.

The invention relates to an insoluble medicine feeding system based on soluble cyclodextrin polymer, with high yield and the application in batch production, wherein said medicine compound is formed by insoluble medicine and cyclodextrin derivant, whose mass ratio is 0.1-100:1; and said insoluble medicine is the one whose solubility is less than 1% in room temperature; the soluble cyclodextrin polymer uses cyclodextrin as crosslink agent to be concentrated with cyclodextrin monomer. The inventive product is not shaped powder, whose average molecular weight can reach 10000.

A liquid preparation of meloxican is prepared from the meloxicam or its medical salt and water-soluble cyclodextrin derivative HP-beta-CD used as solubilizer and stabilizer, proportionally mixing, adding cosolvent, pH regulator and water for injection, heating and membrane filtering. It has long storage time at low temp.

The present invention relates to a medicine composition containing mangiferin and its preparation method. It is characterized by that the mangiferin is contained in the cyclodextrin derivative, and the mixing ratio of both them is as follows: mangiferin 1g and cyclodextrin derivative 3g-30g. It can effectively raise solubility and bioavailability of mangiferin.

The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units.

The present invention is directed to a preserved liquid aqueous pharmaceutical composition comprising one or more etherified cyclodextrin derivatives; one or more water-soluble preservatives; preferably selected from the group consisting of sorbic acid or salts thereof, preferably sodium sorbate, potassium sorbate, calcium sorbate; benzoic acid or salts thereof, preferably sodium benzoate; benzalkonium chloride; benzethonium chloride; cetylpyridinium chloride; sodium metabisulfite; sodium acetate; parabenes and salts thereof, preferably methylparabene, ethylparabene, propylparabene, butylparabene, butylparabene sodium; or combinations thereof; and at least one pharmaceutically active compound which is poorly water-soluble, very poorly water-soluble or water-insoluble. The liquid aqueous pharmaceutical composition provides an acceptable solubility of the pharmaceutically active compound, such as pimobendan, in aqueous solution whereby the water-soluble preservatives retain their effectiveness in the presence of the etherified cyclodextrin derivatives allowing the use in an oral administration form.

The invention discloses a pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound, wherein cyclodextrin or a cyclodextrin derivative is used to include the pinocembrin. The inclusion compound contains the pinocembrin and the cyclodextrin or cyclodextrin derivative in a molar ratio of 1:1-100. The inclusion compound can improve the water solubility of the pinocembrin and give good play of the therapeutic action of the pinocembrin. The inclusion compound is suitable for the preparation of sold dosage forms and liquid dosage forms required by clinics, including infusion solution, water injection, powder injection, oral solution, syrup, tablets, capsules, granules and dispersible tablets. The inclusion compound can be used for preparing drugs for preventing and\or treating cardiovascular and cerebrovascular diseases, particularly brain stroke, as well as drugs for preventing and\or treating bacterial and\or fungal infections.

An object of the present invention relates to a tablet which comprises an active ingredient and a cyclodextrin or a cyclodextrin derivative and rapidly disintegrates in the oral cavity, etc. The present invention provides a tablet in which 70% by mass or more of the components of the tablet is a cyclodextrin or a cyclodextrin derivative and a method for manufacturing a tablet comprising the steps of: mixing constituent components of the tablet which comprises as constituent components an active ingredient and a cyclodextrin or a cyclodextrin derivative and in which 70% by mass or more of the total constituent components of the tablet is the cyclodextrin or the cyclodextrin derivative; and subsequently tableting the resultant mixture.

Disclosed is a lyophilized liposome composition encapsulating a water-soluble drug and a preparation process thereof. The lyophilized liposome composition comprises a water-soluble drug, a phospholipid, a polyethylene glycol-derivatized phospholipid, cholesterol and a lyoprotectant, wherein the lyoprotectant comprises a saccharide and a cyclodextrin or cyclodextrin derivative. The encapsulation rate of the lyophilized liposome composition encapsulating the water-soluble drug is ≧90%.

The invention provides 6-deoxy alpha-amino acid derivative cyclodextrin which is a target substance obtained by the condensation of an amino acid derivative and halogenated cyclodextrin in the presence of alkali. The 6-deoxy alpha-amino acid cyclodextrin derivatives comprise a 6-deoxy thioether alpha-amino acid derivative cyclodextrin, a 6-deoxy sulfoxide alpha-amino acid derivative cyclodextrin and a 6-deoxy sulfonyl alpha-amino acid derivative cyclodextrin. The compounds provided by the invention can be used for reversing the phenomenon of nerve muscle relaxation induced by human or animal muscle relaxants, have rapid reversing and antagonizing effects on muscle relaxation induced by the muscle relaxants, can be used for preparing medicaments with muscle relaxation antagonizing effect, have the characteristics of low production cost and wide muscle relaxation reversing and antagonizing range and have effectively increased clinical application range. More importantly, the safe dose of the compounds provided by the invention is increased by at least one time compared with the known compounds. The general formula (I) of the compounds is shown in the specifications.

The invention discloses a dual-response multiple-medicine delivery system based on cyclodextrin. Firstly, through the action of a donor and a receptor, a macrocyclic molecule cyclodextrin serving as a host and a molecule ferrocene group serving as a guest form a self-inclusion complex; the dissociation and the inclusion of the host to the guest can be realized by utilizing redox regulation and control; the effect that a micromolecular medicine is subjected to adsorption-release through a cavity of the cyclodextrin is realized; secondly, a carbon chain containing an acetal group is introduced to connect a derivative of the cyclodextrin and a silicon dioxide microsphere; in an acid environment, an acetal bond is ruptured; the derivative of the cyclodextrin is quitted; a macromolecule is further released. The medicine delivery system provided by the invention has the characteristics of redox and dual response in the acid environment, moreover, can be used for seriatim or synchronously releasing medicine molecules in different sizes, can be used for controlling administration time, a position and a dosage, and has a favorable application prospect.

The invention belongs to the field of a medicinal preparation and specifically relates to a posaconazole solid dispersion and a preparation method of the solid dispersion and drug use. The invention provides a posaconazole solid dispersion and its drug use. The posaconazole solid dispersion contains posaconazole, a cyclodextrin derivative and a water-soluble or enteric carrier material, wherein mass ratio of posaconazole to the cyclodextrin derivative is 1:1-4 or mass ratio of posaconazole to the cyclodextrin derivative to the water-soluble or enteric carrier material is 1:1-4:0.001-3. The posaconazole solid dispersion can remarkably raise dissolution rate of the difficultly-soluble antifungal agent posaconazole in the small intestine and also can significantly enhance bioavailability of posaconazole. By the use of a dosage form prepared from the solid dispersion, the preparation technology is simple, and quality of the dosage form is stable.

The invention belongs to the technical field of preparation of ceramic water reducers and discloses a cyclodextrin grafted copolymer type ceramic water reducer and a preparation method thereof. The water reducer is prepared from cyclodextrin or a cyclodextrin derivative, 3-(2-methylacryloyl ethoxyl dimethylamine) propanesulfonate, a chain transfer agent, an initiator, a chain terminator and deionized water. Due to a special molecular structure of cyclodextrin, the water reducer prepared by the preparation method has very good water-reducing and dispersing effects and meanwhile the water reducer which is amphoteric ionic polyelectrolyte is good in chemical property and thermal stability, strong in hydratability and insusceptible to the pH value of a solution. In addition, the water reducer prepared by the preparation method provided by the invention further has an enhancing effect on ceramic.

The present invention discloses a method for including andrographolide by using cyclodextrin and its medicinal preparation. The andrographolide is an importent active extract of medicinal plant andrographis. Its inclusion method includes: adding 10-60g of cyclodextrin or its derivative into distilled water and dissolving it; adding 6g of andrographolide extract into 5-10 ml of medicinal methyl alcohol, heating and dissolving it; pouring the cyclodextrin aqueous solution into andrographolide ethyl alcohol solution; ultrasonic vibrating mixed solution in ultrasonic generator for 20-30 min., adopting thin-layer chromatography to identify the cyclodextrin-andrographolide inclusion quality. It does not change chemical property and effective activity of the andrographolide, can be prepared intovarious dosage forms.

Disclosed herein is a composition for preparing a nanoporous material. The composition comprises i) a cyclodextrin derivative, ii) a thermostable matrix precursor, and iii) a solvent for dissolving the components i) and ii). The composition enables the preparation of a low dielectric constant film in which nanopores with a size of 20 Å or less are uniformly distributed.